COMMITMENTS AND CONTINGENCIES (Details Narrativec) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended
	Jun. 03, 2025	Jul. 02, 2024	Jan. 23, 2024	Nov. 21, 2023	Jun. 25, 2022	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Oct. 31, 2024	Jul. 31, 2024
Stock based compensation						$ 0	$ 108,297	$ 0	$ 216,889
Payment of additional tax								99,644
Research and Development costs								22,966	22,966
Awarded shares		240,000
Patent-related expenses								$ 17,218
Additional stock consideration		$ 264,000		$ 501,600
Settelment amount										$ 37,993	$ 37,880
Complementary compensation Shares								440,000
Purchase price			$ 637,080
General and administrative expenses [Member] | National Medicines Agency [Member]
Stock based compensation						$ 288,110	231,750	$ 533,420	463,500
Research and Development costs								50,052
Cana Laboratories [Member]
Stock based compensation							$ 231,750	83,719	$ 463,500
consulting agreement [Member]
Stock based compensation								$ 68,550
Equity issued in settlement of liabilities	$ 70,000
Issuance of common stock	150,000
Phase 1 [Member]
Project cost					$ 838,450
Phase 2 [Member]
Project cost					$ 907,084
Four Third Party Consultants [Member]
Awarded shares				970,000
Awarded share value				$ 999,100